The inherited thrombophilias: Genetics, epidemiology, and laboratory evaluation

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 17, Issue 3, 2003, Pages 397-411

  Buchanan, Glenn S ^b   Rodgers, George M ^b   Branch, D Ware ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

Activated protein C resistance; Antithrombin deficiency; Dysfibrogenaemia; Factor V Leiden; Hyperhomocysteinaemia; Protein C deficiency; Protein S deficiency; Prothrombin gene mutation; Thrombophilia; Venous thrombosis and thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9A; COMPLEMENT COMPONENT C4 BINDING PROTEIN; CYSTATHIONINE BETA SYNTHASE; FIBRIN; FIBRINOGEN; HEPARAN; HEPARIN; HOMOCYSTEINE; METHIONINE SYNTHASE; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN; SEX HORMONE; THROMBIN; UNINDEXED DRUG; VITAMIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; ANTITHROMBIN DEFICIENCY; BLOOD CLOTTING DISORDER; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG MEGADOSE; DYSFIBRINOGENEMIA; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERPROTHROMBINEMIA; LABORATORY TEST; PHYSICIAN; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SKIN NECROSIS; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION;

EID: 0038042286     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6934(03)00010-5     Document Type: Review

References (47)

1. Goodnight SH & Hathaway WE. Disorders of Hemostasis and Thrombosis: A Clinical Guide, 2nd edn. New York: McGraw-Hill, 2001.
2. Seligsohn U & Lubetsky A. Genetic susceptibility to venous thrombosis. New England Journal of Medicine 2001; 344: 1222-1231.
3. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet 1999; 353: 1167-1173.
4. Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications. Annals of Internal Medicine 2001; 135: 367-373.
5. Howell WH & Holt E. Two new factors in blood coagulation - Heparin and pro-antithrombin. American Journal of Physiology 1918; 47: 328-341.
6. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombosis et Diathesis Haemorrhagica 1965; 13: 516-530.
7. Seegers WH, Johnson JF & Fell C. An antithrombin reaction related to prothrombin activation. American Journal of Physiology 1954; 176: 97-103.
8. Prochownik EV, Antonarakis S, Bauer KA et al. Molecular heterogeneity of inherited antithrombin III deficiency. New England Journal of Medicine 1983; 308: 1549-1552.
9. Online database available at: www.med.ic.ac.uk/divisions/7/antithrombin/index.htm.
10. Samama M, Gerotziafas G, Conrad J et al. Clinical aspects and laboratory problems in hereditary thrombophilia. Haemostasis 1999; 29: 76-99.
11. Reitsma PH. Genetic heterogeneity in hereditary thrombophilia. Haemostasis 2000; 30(supplement 2): 1-10.
12. Franco RF & Reitsma PH. Genetic risk factors of venous thrombosis. Human Genetics 2001; 109: 369-384.
13. Beck EA, Charache P & Jackson DP. A new inherited coagulation disorder caused by an abnormal fibrinogen (fibrinogen Baltimore). Nature 1965; 208: 143-145.
14. Online database available at: www.geht.org/pages/database_ang.html.
15. Roberts HR, Stinchcombe TE & Gabriel DA. The dysfibrinogenaemias. British Journal of Haematology 2001; 114: 249-257.
16. Haverkate F & Samama M. Familial dysfibrinogenaemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thrombosis and Haemostasis 1995; 73: 151-161.
17. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. Journal of Biological Chemistry 1976; 251: 355-363.
18. Griffin JH, Evatt B, Zimmerman TS et al. Deficiency of protein C in congenital thrombotic disease. Journal of Clinical Investigation 1981; 68: 1370-1373.
19. Online database available at: www.xs4all.nl/~reitsma/Prot_C_home.htm.
20. Di Scipio RG, Hermodson MA, Yates SG & Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry 1977; 16: 698-706.
21. Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. Journal of Biological Chemistry 1980: 255: 5521-5524.
22. Comp PC, Nixon RR, Cooper MR & Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. Journal of Clinical Investigation 1984; 74: 2082-2088.
23. Hackeng TM, Van't Veer C, Meijers JC & Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. Journal of Biological Chemistry 1994; 269: 21051-21058.
24. Online database available at: www.med.unc.edu/isth/proteins.htm.
25. Dahlback B, Carlsson M & Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proceedings of the National Academy of Sciences of the USA 1993; 90: 1004-1008.
26. Dahlback B & Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proceedings of the National Academy of Sciences of the USA 1994; 91: 1396-1400.
27. Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
28. Robetorye RS & Rodgers GM. Update on selected inherited venous thrombotic disorders. American Journal of Hematology 2001; 68: 256-268.
29. Rees DC, Cox M & Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
30. Poort SR, Rosendaal FR, Reitsma PH & Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
31. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. American Journal of Pathology 1969; 56: 111-128.
32. Den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinaemia and venous thrombosis: A meta-analysis. Thrombosis and Haemostasis 1998; 80: 874-877.
33. Makris M. Hyperhomocysteinaemia and thrombosis. Clinical and Laboratory Haematology 2000; 22: 133-143.
34. Kang SS, Zhou J, Wong PW et al. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. American Journal of Human Genetics 1988; 43: 414-421.
35. Key NS & McGlennen RC. Hyperhomocyst(e)inemia and thrombophilia. Archives of Pathology and Laboratory Medicine 2002; 126: 1367-1375.
36. Koster T, Blann AD, Briet E et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
37. Kamphuisen PW, Eikenboom JC & Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arteriosclerosis, Thrombosis and Vascular Biology 2001; 21: 731-738.
38. Chandler WL, Rodgers GM, Spouse JT & Thompson AR. Elevated hemostatic factor levels as potential risk factors for thrombosis. Archives of Laboratory Medicine 2002; 126: 1405-1414.
39. Lockwood CJ. Inherited thrombophilias in pregnant patients: Detection and treatment paradigm. Obstetrics & Gynecology 2002; 99: 333-341.
40. Geerts WH, Code KI, Jay RM et al. A prospective study of venous thromboembolism after major trauma. New England Journal of Medicine 1994; 331: 1601-1606.
41. Caprini JA, Arcelus JI & Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Seminars in Hematology 2001; 38(supplement 5): 12-19.
42. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. New England Journal of Medicine 2000; 342: 374-380.
43. Van Cott EM, Laposata M & Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Archives of Pathology and Laboratory Medicine 2002; 126: 1281-1295.
44. Rosendaal FR, Helmerhorst FM & Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thrombosis and Haemostasis 2001; 86: 112-123.
45. Vandenbroucke JP, Koster T, Briet E et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
46. Martinelli I, Taioli E, Bucciarelli P et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arteriosclerosis, Thrombosis and Vascular Biology 1999; 19: 700-703.
47. Writing group for the Women's Health Initiative investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002; 288: 321-333.